Commentary - (2025) Volume 13, Issue 4
Received: 01-Aug-2025, Manuscript No. JCMG-26-185551;
Editor assigned: 03-Aug-2025, Pre QC No. P-185551;
Reviewed: 18-Aug-2025, QC No. Q-185551;
Revised: 23-Aug-2025, Manuscript No. R-185551;
Published:
29-Aug-2025
, DOI: 10.37421/2472-128X.2025.13.354
Citation: Morales, Javier. ”Precision Oncology: Revolutionizing Cancer Treatment Through Genomics.” J Clin Med Genomics 13 (2025):354.
Copyright: © 2025 Morales J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Precision oncology represents a paradigm shift in cancer care, driven by the integration of individual genomic information to tailor therapeutic strategies. This innovative approach involves identifying specific molecular alterations within a patient's tumor, which then guides the selection of targeted therapies or immunotherapies. The aim is to enhance treatment efficacy while simultaneously minimizing the toxic side effects often associated with traditional cytotoxic chemotherapy [1].
Comprehensive genomic profiling (CGP) has demonstrated well-established clinical utility, particularly in non-small cell lung cancer (NSCLC), where it aids in identifying targetable alterations that inform therapy selection. Its value is increasingly being recognized across a broader range of cancer types, revealing a diverse array of actionable mutations that can be matched with existing targeted therapies or enrollment in clinical trials [2].
Tumor mutational burden (TMB) is emerging as a significant predictive biomarker for patient response to immune checkpoint inhibitors (ICIs) across a variety of cancer types. Tumors with a high TMB are often associated with an increased neoantigen load, which can bolster the immune system's ability to recognize and eliminate cancer cells. However, standardization of TMB measurement and interpretation remains an active area of research to ensure its reliable application in clinical settings [3].
Liquid biopsies, especially the analysis of circulating tumor DNA (ctDNA), offer a minimally invasive method for detecting cancer-driving mutations, monitoring treatment response, and identifying minimal residual disease (MRD). ctDNA analysis can effectively complement traditional tissue biopsies by capturing tumor heterogeneity and providing real-time insights into tumor evolution, thus personalizing therapeutic strategies [4].
Genomic alterations within DNA repair pathways are critical targets in the field of precision oncology, with particular relevance in cancers such as ovarian and prostate cancer. Tumors exhibiting deficiencies in homologous recombination repair (HRR), often characterized by BRCA1/2 mutations, display heightened sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors. Identifying these specific genomic vulnerabilities enables the rational deployment of targeted agents, leading to substantial clinical benefits for patients with these molecular profiles [5].
The emergence of drug resistance presents a formidable challenge within precision oncology. A thorough understanding of the molecular mechanisms underlying acquired resistance to targeted therapies is paramount for developing effective strategies to overcome or prevent it. Genomic studies, including the longitudinal monitoring of ctDNA, are indispensable for identifying resistance mutations and guiding subsequent treatment decisions, such as switching to alternative targeted agents or employing combination therapies [6].
Genomic databases and sophisticated bioinformatic tools are essential components of precision oncology, facilitating the interpretation of extensive genomic data. These resources are instrumental in pinpointing novel driver mutations, classifying tumors, and matching patients to appropriate targeted therapies or clinical trials. The ongoing development and meticulous curation of these databases are crucial for advancing our comprehension of cancer genomics and its practical clinical applications [7].
The implementation of precision oncology into routine clinical practice encounters several obstacles, including the high cost of testing, disparities in access to genomic diagnostics, and the necessity for specialized personnel trained in interpreting complex genomic results. Ensuring equitable access to these advanced diagnostic and therapeutic modalities is vital to prevent the exacerbation of existing healthcare disparities. Collaborative endeavors among researchers, clinicians, policymakers, and industry stakeholders are indispensable to surmount these barriers and fully realize the potential of precision oncology for all patients [8].
Artificial intelligence (AI) and machine learning (ML) are playing an increasingly significant role in precision oncology. These technologies possess the capability to analyze vast datasets encompassing genomic, clinical, and imaging information, thereby identifying intricate patterns, predicting treatment responses, discovering novel biomarkers, and optimizing drug development processes. AI/ML algorithms hold the promise of accelerating the discovery and widespread adoption of personalized cancer therapies by extracting deeper insights from complex biological data [9].
The integration of germline genetic information alongside somatic tumor profiling is substantially broadening the scope of precision oncology. The identification of germline predisposition mutations can inform risk assessment and preventative strategies for cancer, while understanding the complex interplay between germline and somatic alterations offers a more holistic view of an individual's cancer. This comprehensive, multi-omic approach is fundamental to further refining personalized cancer treatments and ultimately improving patient outcomes [10].
Precision oncology is fundamentally transforming cancer care by leveraging genomic information to personalize treatment plans for individual patients. This patient-centric approach aims to identify specific molecular drivers within a tumor, enabling the selection of therapies that are more effective and less toxic than conventional chemotherapy [1].
Comprehensive genomic profiling (CGP) has proven its clinical value, especially in non-small cell lung cancer (NSCLC), by pinpointing targetable genetic alterations that guide therapeutic choices. Its application is expanding beyond NSCLC, revealing a wider spectrum of actionable mutations across various cancers that can be matched with available targeted therapies or clinical trials [2].
Tumor mutational burden (TMB) is emerging as a key biomarker for predicting response to immune checkpoint inhibitors (ICIs) across diverse cancer types. High TMB correlates with a greater load of neoantigens, which can enhance the immune system's ability to target and eliminate cancer cells. However, standardization in TMB measurement is still under development to ensure consistent clinical utility [3].
Liquid biopsies, particularly the analysis of circulating tumor DNA (ctDNA), provide a less invasive means to detect cancer-related mutations, monitor treatment effectiveness, and identify minimal residual disease. ctDNA analysis complements tissue biopsies by capturing tumor heterogeneity and offering real-time information on tumor evolution, thereby personalizing treatment approaches [4].
Targeting genomic alterations in DNA repair pathways is a significant strategy in precision oncology, particularly relevant for cancers like ovarian and prostate cancer. Tumors with defects in homologous recombination repair (HRR), such as those with BRCA1/2 mutations, often show remarkable sensitivity to PARP inhibitors, allowing for tailored therapy with improved outcomes [5].
Drug resistance remains a critical challenge in precision oncology. Understanding the molecular mechanisms behind acquired resistance to targeted therapies is essential for developing strategies to overcome or prevent it. Genomic studies, including longitudinal ctDNA monitoring, are crucial for identifying resistance mutations and guiding subsequent treatment decisions, such as switching therapies or using combination treatments [6].
Genomic databases and bioinformatics tools are indispensable for precision oncology, as they enable the interpretation of vast amounts of genomic data. These resources help in identifying new driver mutations, classifying tumors, and matching patients to targeted therapies or clinical trials, furthering our understanding and application of cancer genomics [7].
Implementing precision oncology in clinical practice faces challenges related to cost, accessibility of genomic testing, and the need for skilled personnel to interpret results. Ensuring equitable access is vital to prevent widening healthcare disparities. Collaborative efforts are required to overcome these barriers and maximize the benefits of precision oncology for all patients [8].
The role of artificial intelligence (AI) and machine learning (ML) is rapidly growing in precision oncology. These technologies can process extensive genomic, clinical, and imaging data to identify patterns, predict treatment outcomes, discover biomarkers, and optimize drug development, thereby accelerating personalized cancer care [9].
Integrating germline and somatic genomic information enhances precision oncology. Germline predisposition mutations can inform risk assessment and prevention, while understanding the interplay between germline and somatic alterations provides a more complete picture of an individual's cancer, crucial for refining personalized treatments and improving outcomes [10].
Precision oncology revolutionizes cancer care by tailoring treatments based on individual genomic profiles, identifying specific molecular alterations to guide targeted or immunotherapies, thereby improving efficacy and reducing toxicity. Comprehensive genomic profiling (CGP) is established in NSCLC and expanding to other cancers, aiding therapy selection. Tumor mutational burden (TMB) is a promising biomarker for immunotherapy response. Liquid biopsies via ctDNA analysis offer a minimally invasive way to detect mutations, monitor response, and track tumor evolution. Genomic alterations in DNA repair pathways are critical targets, with PARP inhibitors showing efficacy in HRR-deficient tumors. Drug resistance mechanisms are being elucidated through genomic studies, informing strategies to overcome resistance. Genomic databases and bioinformatics are crucial for interpreting data and matching patients to therapies. Implementation challenges include cost and access, necessitating collaborative efforts for equitable access. Artificial intelligence and machine learning are increasingly used to analyze complex data for pattern recognition, prediction, and drug discovery. Integrating germline and somatic genomics provides a comprehensive view for refining personalized treatments.
None
None
Journal of Clinical & Medical Genomics received 391 citations as per Google Scholar report
